ICUI (ICU Medical Inc)
Insider Trading Activity
Every open-market purchase and sale reported by ICUI officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-01 | Brian Michael Bonnell | Chief Financial Officer | Sell | — | — |
| 2026-08-31 | Brian Michael Bonnell | Chief Financial Officer | Sell | — | — |
| 2026-08-13 | Daniel Woolson | VP, GM-Infusion Capital | Sell | — | — |
| 2026-08-12 | Ben Sousa | Chief Information Officer | Sell | — | — |
| 2026-08-11 | ELISHA W FINNEY | Director | Sell | — | — |
| 2026-08-11 | Christian B. Voigtlander | Chief Operating Officer | Sell | — | — |
| 2026-05-22 | Daniel Woolson | President | Sell | — | — |
| 2026-05-15 | Virginia Ruth Sanzone | VP, General Counsel | Sell | — | — |
| 2026-05-13 | ELISHA W FINNEY | Director | M | — | — |
| 2026-05-13 | Laurie Hernandez | Director | M | — | — |
| 2026-05-13 | KOLLEEN T KENNEDY | Director | M | — | — |
| 2026-05-13 | Donald Abbey | Director | M | — | — |
| 2026-05-13 | David C. Greenberg | Director | MIXED | — | — |
| 2026-05-13 | David F Hoffmeister | Director | M | — | — |
| 2026-03-26 | Donald Abbey | Director | J | — | — |
| 2026-03-16 | Virginia Ruth Sanzone | VP, General Counsel | MIXED | — | — |
| 2026-03-16 | Daniel Woolson | VP, GM-Infusion Capital | MIXED | — | — |
| 2026-03-16 | Brian Michael Bonnell | Chief Financial Officer | MIXED | — | — |
| 2026-03-16 | Vivek Jain | Chairman and CEO | MIXED | — | — |
| 2026-03-16 | Christian B. Voigtlander | Chief Operating Officer | MIXED | — | — |
| 2026-03-16 | Ben Sousa | Chief Information Officer | MIXED | — | — |
| 2026-03-09 | Vivek Jain | Chairman and CEO | MIXED | — | — |
| 2026-03-09 | Brian Michael Bonnell | Chief Financial Officer | MIXED | — | — |
| 2026-03-09 | Daniel Woolson | VP, GM-Infusion Capital | MIXED | — | — |
| 2026-03-09 | Christian B. Voigtlander | Chief Operating Officer | MIXED | — | — |
| 2026-03-09 | Virginia Ruth Sanzone | VP, General Counsel | MIXED | — | — |
| 2026-03-09 | Ben Sousa | Chief Information Officer | MIXED | — | — |
| 2025-11-25 | Daniel Woolson | VP, GM-Infusion Capital | Sell | — | — |
| 2025-11-12 | Virginia Ruth Sanzone | VP, General Counsel | Sell | — | — |
| 2025-11-12 | ELISHA W FINNEY | Director | MIXED | — | — |
| 2025-09-15 | Vivek Jain | Chairman and CEO | G | — | — |
| 2025-08-27 | David C. Greenberg | Director | Buy | — | — |
| 2025-08-14 | Vivek Jain | Chairman and CEO | Buy | — | — |
| 2025-05-30 | Virginia Ruth Sanzone | VP, General Counsel | Sell | — | — |
| 2025-05-28 | Christian B. Voigtlander | Chief Operating Officer | MIXED | — | — |
| 2025-05-23 | Christian B. Voigtlander | Chief Operating Officer | MIXED | — | — |
| 2025-05-21 | Christian B. Voigtlander | Chief Operating Officer | MIXED | — | — |
| 2025-05-20 | ELISHA W FINNEY | Director | Sell | — | — |
| 2025-05-19 | Christian B. Voigtlander | Chief Operating Officer | MIXED | — | — |
| 2025-05-15 | Ben Sousa | Chief Information Officer | Sell | — | — |
| 2025-05-15 | Christian B. Voigtlander | Chief Operating Officer | MIXED | — | — |
| 2025-05-14 | ELISHA W FINNEY | Director | M | — | — |
| 2025-05-13 | David F Hoffmeister | Director | M | — | — |
| 2025-05-13 | Laurie Hernandez | Director | M | — | — |
| 2025-05-13 | Donald Abbey | Director | M | — | — |
| 2025-05-13 | David C. Greenberg | Director | MIXED | — | — |
| 2025-05-13 | KOLLEEN T KENNEDY | Director | M | — | — |
| 2025-03-17 | Brian Michael Bonnell | Chief Financial Officer | M | — | — |
| 2025-03-17 | Virginia Ruth Sanzone | VP, General Counsel | MIXED | — | — |
| 2025-03-17 | Ben Sousa | Chief Information Officer | MIXED | — | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| — | 10%+ Owner | 2,500,000 | — |
| — | — | 1,670,000 | — |
| — | — | 1,670,000 | — |
| — | Director | 1,203,074 | — |
| — | Chairman and CEO | 281,865 | — |
| — | Chief Financial Officer | 70,297 | — |
| — | Director | 69,942 | — |
| — | Chief Operating Officer | 37,377 | — |
| — | Director | 21,941 | — |
| — | Director | 19,862 | — |
| — | VP, General Counsel | 19,460 | — |
| — | VP, GM-Infusion Capital | 17,062 | — |
| — | Chief Financial Officer, | 16,274 | — |
| — | Director | 12,794 | — |
| — | Chief Financial Officer | 8,946 | — |
| — | Director | 8,460 | — |
| — | Vice President and Gen'l Mgr. | 7,841 | — |
| — | Vice President and Gen'l Mgr. | 7,048 | — |
| — | Director | 6,004 | — |
| — | Director | 6,004 | — |
| — | Director | 4,871 | — |
| — | Director | 4,862 | — |
| — | Director | 4,539 | — |
| — | Chief Accounting Officer | 4,447 | — |
| — | Director | 4,284 | — |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the ICUI quote page; the site-wide leaderboard is on the insider transactions hub.